



ProActive Investors

John Dawson – CEO

23rd June 2011



**Proven
Business
Model**

**Results
History**

Outlook



Background to Alliance

- ❑ Started in 1998 as a speciality pharma company
- ❑ Features of a speciality pharma company
 - ❑ Serving patients' needs in smaller disease areas
 - ❑ Products obtained from
 - ❑ Acquisitions
 - ❑ In-licensing
 - ❑ Development (but not Research)
 - ❑ Many are small to medium companies, but some are large, eg
 - ❑ Shire £2.2bn sales; £9.2bn valuation
 - ❑ King (US), \$1.8bn sales, bought by Pfizer in 2010 for \$3.6bn
 - ❑ Meda £1.1bn sales; £1.5bn Mkt cap
- ❑ Alliance has grown to £50m sales in 2010
 - ❑ 19 acquisition deals > 50 products
 - ❑ Several in-licensing deals
 - ❑ "Own" sales and marketing in UK, Ireland and China
 - ❑ Sales into 25 countries



Proven three-stage Business Model

1. Acquisition of established medicines to provide firm financial bedrock

- ❑ Typically prescription medicines that have stood the test of time
- ❑ Brands with history of sustainable sales
- ❑ Niche brands with limited competition
- ❑ Sustainability of sales into the future

2. Assess for growth potential


- ❑ Economics of brand building / promotion
- ❑ Scope / requirement for commercial deals
- ❑ Territorial expansion

3. Selective investment in brand-building: examples

- ❑ Nu-Seals Ireland, 2002 – 2005; sales growth £2.0 to £3.5m
- ❑ Symmetrel UK, 2003 – 2006; sales growth £0.6m to £1.6m
- ❑ Hydromol UK, 2006 – ongoing; sales growth £0.9m to £2.9m
- ❑ ImmuCyst UK, 2001 – ongoing; sales growth £0 to £3.6m



Niche brands that have stood the test of time



Longevity of niche prescription brands

Average age
33 years


Product	2010 Sales £m	Launched By	Launch Date	Alliance Since	Description
Deltacortril	13.5	Pfizer	1957	2006	Steroid to control immune system in a variety of conditions
Nu-Seals	4.8	Lilly	1978	2002	Low dose aspirin for prevention of heart attacks and strokes
Forceval	4.2	Unigreg	1970	2004	Complete supplement of micro-nutrients
Toxicology product	4.1*	Berk Pharmaceuticals	1991	2010	Toxicology product sold into Government stockpile on a 2½ year cycle
ImmuCyst	3.6*	Cambridge Labs	2001	2010	Immunotherapy for non muscle invasive bladder cancer
Hydromol	2.9	Quinoderm	1987	2006	Range of emollient products used in the management of eczema and other dry skin conditions
Syntocinon/ Syntometrine	2.4	Sandoz	1956	1998/ 2006	Childbirth: assist labour/prevent haemorrhage after delivery
Xenazine / Nitoman	2.4*	Roche	1971	2010	Treatment for the alleviation of a wide range of hyperkinetic movement disorders (e.g. chorea in Huntington's disease)
Buccastem	1.8	Reckitt & Colman	1987	2009	Buccal tablet for treatment of nausea and vomiting
Symmetrel	1.5	Geigy	1970	2001	Parkinson's disease

* Pro forma assuming full year of ownership



Sustainability of sales from non-promoted products

Like for like sales of non-promoted products*, indexed to 100 at January 2003




*Excludes Deltacortril



Risk reduction through diversity – over 50 products

Pro forma 2010 revenue segmentation



Shaded = promoted



Selective promotion when economically justified

ImmuCyst +

- Immunotherapy for non-muscle-invasive bladder cancer
- Brought into Alliance through Cambridge Labs acquisition
- Promoted using bespoke contract field force
- 2010 sales £3.6m and still growing

Hydromol +

- Range of emollients for remission of eczema
- Acquired from Ferndale Labs in 2006
- Using bespoke contract field force covering hospital and general practice
- Grew from £0.9m to £2.9m and still growing




Proven
Business
Model

**Results
History**

Outlook



Strong record of growing Sales



Five year compound annual growth rate to 2010:

13% organic

19% acquisitions

32% combined

** 10 months annualised*




2010 Sales growth

		2010 £m	2009 £m	Growth £m
Deltacortril	Improved production volumes	13.5	8.5	+5.0
Nu-Seals	Adverse exchange rate movement, 2009 benefitted from competitor stock issues	4.8	5.8	(1.0)
Dermatology (excl Timodine)	18% growth	6.0	5.1	+0.9
Cambridge Laboratories	Acquired February 2010. Within this figure Oncology grew 16%	11.7	-	+11.7
Buccastem and Timodine	Acquired August 2009	2.9	1.0	+1.9
Other	Stable sales from core non-promoted brands	11.0	10.8	+0.2
Total	60% growth overall	49.9	31.2	+18.7



Significant increases in Profits



* 10 months annualised



2010 P&L

£'m	Growth	2010	2009
Sales	60%	49.9	31.2
Gross profit	68%	30.4	18.1
<i>Gross margin %</i>		60.9%	58.0%
Operating costs		(10.9)	(6.9)
Amortisation		(0.8)	-
Operating profit (pre-exceptionals)	66%	18.7	11.3
<i>Operating profit %</i>		37.5%	36.0%
Financing costs		(2.3)	(2.7)
Adjusted PBT (pre-exceptionals)	91%	16.4	8.6
Exceptional items		(3.5)	(2.8)
Reported PBT		12.9	5.8
Tax		(3.9)	(1.7)
Profit After Tax		9.0	4.1
Basic EPS		3.96p	2.37p
Adjusted EPS	43%	5.07p	3.55p



2010 results – summary

- ❑ Sales up 60% to £49.9m
- ❑ Operating profit* up 66% to £18.7m
- ❑ Pre-tax profit* up 91% to £16.4m
- ❑ Adjusted basic EPS up 43% to 5.07p
- ❑ Cash from operations up 68% to £17.9m
- ❑ Net bank debt down £4.7m to £17.0m, just 0.9 times EBITDA
- ❑ Total dividend up 90% to 0.57p

*Before exceptional items



Latest Acquisition:
Two products from Reckitt Benckiser

Anbesol
and
Ashton & Parsons Infant Powders
April 2011



Anbesol and Ashton & Parsons Infant Powders

- ❑ Two well established products
- ❑ Anbesol
 - ❑ Relief of Mouth Pain
 - ❑ Sales £1.3m pa
- ❑ Ashton & Parsons Infant Powders
 - ❑ Teething pain and associated colic
 - ❑ Sales £0.8m pa
 - ❑ Production issues to resolve
- ❑ Similar margins to Alliance products
- ❑ Cash consideration of £2.55m, funded from our new £20m RCF (which is otherwise undrawn)
- ❑ Being divested by Reckitt Benckiser at request of European Commission following RB's takeover of SSL



Proven
Business
Model

Results
History

Outlook



Growth outlook

Trading

- ❑ Dermatology
 - ❑ 2010 sales of £7.1m
 - ❑ 18% like for like growth in 2010
 - ❑ Increased promotional investment in 2010
- ❑ Oncology
 - ❑ 2010 sales of £5.0m (pro forma)
 - ❑ 16% growth in 2010
 - ❑ Looking for further products to add to portfolio
- ❑ Forceval China
 - ❑ Good medium term growth potential
- ❑ Non-promoted products provide modest growth
- ❑ Deltacortril
 - ❑ Increased competition predicted for past two years
 - ❑ Came into effect May 2010


External Growth

- ❑ Acquisitions
 - ❑ Good track record
 - ❑ Products
 - ❑ Companies
- ❑ In-licensing
 - ❑ Dermatology
 - ❑ Oncology
- ❑ Financing capacity
 - ❑ New bank facilities
 - ❑ Good response to last two equity raisings



Acquisitions Record

- 19 deals in 13 years
- 50+ products



Financial outlook

❑ Stability of financing

- ❑ New facilities in place November 2010 until end 2014
- ❑ Interest rate reduced from 9% to 4%
- ❑ c. 75% of interest is fixed
- ❑ Good headroom on covenant ratios:
 - ❑ Interest cover
 - ❑ Cash generation : debt servicing cash
 - ❑ Net debt : EBITDA
- ❑ £20m revolving credit facility as an acquisitions fund
- ❑ Low gearing gives significant additional borrowing capacity

❑ Dividends growing

- ❑ Debt being paid down
- ❑ No significant day to day capital requirements
- ❑ 2010 full year dividend 0.57p per share, up 90%, covered c.9 times
- ❑ Progressive dividend policy



Appendices



2010 Cash Flow

£'m	2010	2009
Operating profit	18.7	11.3
Depreciation and amortisation	1.0	0.1
Working capital	(1.8)	(0.8)
Cash flow from trading	17.9	10.6
Interest	(2.0)	(2.7)
Refinancing	(1.5)	-
Capital expenditure	(0.9)	(0.2)
Tax paid	(1.3)	(0.3)
Cash generation	12.2	7.4
Acquisitions	(14.3)	(7.7)
Equity raised	7.5	3.7
Dividend	(0.7)	-
Underlying debt reduction	4.7	3.4



2010 Balance Sheet

£'m	Dec 10	Dec 09	Change
Product licences	60.3	44.9	+15.4
Inventories	4.5	3.0	+1.5
Trade and other receivables	9.7	7.7	+2.0
Trade and other payables	(11.9)	(7.1)	(4.8)
Other net assets	(4.6)	(2.7)	(1.9)
<i>Net cash</i>	2.0	0.4	+1.6
<i>Bank loans</i>	(19.0)	(22.1)	+3.1
Net bank debt	(17.0)	(21.7)	+4.7
Convertible loan stock	(4.9)	(7.5)	+2.6
Equity	36.1	16.6	+19.5



Top 20 Investors: 8 April 2011

Holder / Fund Manager	No. of Shares	% Holding
Director & Related	69,860,893	29.53%
Nigel Wray	31,619,995	13.36%
Aviva Investors Global Services	23,991,755	10.17%
MVM Life Science Partners	19,300,000	8.16%
Slater Investments	7,344,320	3.10%
Hargreave Hale	6,664,250	2.82%
Old Mutual Asset Managers (UK)	6,377,263	2.70%
LGT Capital Management	5,371,071	2.27%
Barclays Wealth	5,147,175	2.18%
Taylor Young Investment Management	4,804,650	2.03%
Investec Asset Management	4,750,000	2.01%
KBL European Private Bankers	2,950,895	1.25%
Henderson New Star	2,900,000	1.23%
Hargreaves Lansdown Asset Management	2,863,945	1.21%
Cavendish Asset Management	2,830,000	1.20%
BlackRock Investment Management (UK)	2,600,000	1.10%
TD Waterhouse Investor Services	2,593,253	1.10%
JM Finn & co	2,401,183	1.01%
Seymour Pierce	2,091,290	0.88%
Redmayne Bentley Stockbrokers	1,819,160	0.77%

Total No of Share Owners - 897

No of Shares in Issue – 236,614,917



Convertible Unsecured Loan Stock

- ❑ £4.5m of CULS remaining, paying 8% coupon
- ❑ Was £7.5m, but £3.0m converted since March 2010
- ❑ Convertible at the option of the holders at any time up to 30 November 2013 at 21 pence per share
- ❑ 21.5m additional shares if all £4.5m convert
- ❑ Otherwise redeemed at par
- ❑ Publicly traded with a current price c. £1.50*
- ❑ Held mainly by a small number of income funds

*As at 21 June 2011



Board members



John Dawson, CEO
Pharmacist, MSc Finance; > 40yrs sector experience, founder of Alliance



Richard Wright, Finance Director & Company Secretary: MA, Chartered Accountant, >20 years experience across various industries, joined 2007



Tony Booley, Portfolio Director – Established Products & International
BSc Physiology, MBA, Chartered Marketer; 30yrs sector experience, with Alliance since 1998



Peter Butterfield, Portfolio Director – Oncology & Dermatology


Ex- UK Commercial Manager of Cambridge Laboratories Ltd, graduated from University of Edinburgh with BSc (Hons) specialising in neurotransmitter mechanisms.



Michael Gatenby, Non Executive Chairman
MA. FCA ex-director of Hill Samuel and Co, ex-Vice Chairman of Charterhouse Bank. Holds a number of non executive directorships



Andrew Smith, Non Executive Director
Senior positions held at SmithKline Beecham Pharmaceuticals, Diversified Health Systems Europe, Cerebrus plc and Parexel International



Paul Ranson, Non Executive Director
LL.B Barrister Solicitor. >25 years sector experience



Thomas Casdagli, Non Executive Director
Partner in MVM Life Science Partners, Chartered Accountant, graduated from Oxford in Molecular and Cellular Biochemistry, joined March 2009



Product portfolio

Dermatology Products		
BRAND	NON-PROPRIETARY NAME	USES
Acnival	2% salicylic acid	A medicated cleanser for the treatment and prevention of acne.
Alphaderm	hydrocortisone and urea	An anti-inflammatory and hydrating cream used in the treatment of inflammatory dermatoses such as eczema and psoriasis.
Aquadrate	10% urea	A hydrating cream used in the treatment of dry, scaling and itchy skin disorders. Including: ichthyosis and hyperkeratotic skin conditions associated with atopic eczema, xeroderma, iasteatosis and other chronic dry skin conditions.
Atarax	hydroxyzine hydrochloride	For pruritus (itching) associated with acute and chronic urticaria in children and adults. Also for anxiety in adults.
Dermamist	white soft paraffin	Treatment of dry skin conditions including eczema, ichthyosis and pruritus of the elderly.
Hydromol Cream	sodium pyrrolidone carboxylate 2.5%.	Cream for the treatment of dry skin conditions including dermatitis, eczema, ichthyosis and senile pruritus.
Hydromol Bath & Shower Emollient	light liquid paraffin (37.8%) and isopropyl myristate (13%)	For the treatment of dry skin conditions such as eczema, ichthyosis and senile pruritus.
Hydromol Ointment	yellow soft paraffin (30%) and emulsifying wax (30%)	Ointment for moisturising and softening dry skin. May be used as a soap substitute.
Hydromol Intensive	10% urea	A hydrating cream used in the treatment of dry, scaling and itchy skin disorders. Including: ichthyosis and hyperkeratotic skin conditions associated with atopic eczema, xeroderma, iasteatosis and other chronic dry skin conditions.
Meted	3% salicylic acid and 5% sulphur	A medicated shampoo for the treatment of seborrhoeic dermatitis, scalp dermatitis and dandruff. Relieves the itching, irritation, erythema and flaking.
Naseptin	chlorhexidine and neomycin	An antimicrobial cream for inside the nose. It is used for eradicating staphylococcus infections in the nose.



Product portfolio

BRAND	NON-PROPRIETARY NAME	USES
Occlusal	26% salicylic acid	A topical solution for the treatment and prevention of common and planar warts.
Permitabs	potassium permanganate	A mild antiseptic used to clean and deodorise oozing eczematous skin conditions and wounds.
Pentrax	fractar 5 coal tar extract	A shampoo for the treatment of seborrhoeic dermatitis, scalp dermatitis and dandruff. Relieves the itching, irritation, erythema, flaking and scaling.
Timodine	nystatin 100,000 IU/g, hydrocortisone 0.5%w/w, dimeticone 350 10% w/w, benzalkonium chloride solution 0.2% w/w	Anti-fungal and anti-bacterial skin cream used for treating inflamed and infected skin conditions in which the Candida albicans fungus is a factor. Uses include treatment of severe nappy rash, eczema and other dermatoses.

Oncology Products

BRAND	NON-PROPRIETARY NAME	USES
Gelclair *	polyvinylpyrrolidone	A viscous gel specially formulated to aid the management of lesions of the oral mucosa. It forms a protective film that, by adhering to the mucosa of the oropharyngeal cavity, can prevent further irritations thus contributing to the rapid relief of pain.
ImmuCyst *	bacillus of calmette and guérin	Indicated for intra-vesicular use in the treatment and prophylaxis of primary or recurrent carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis following transurethral resection (TUR) of primary or recurrent stage Ta and/or T1 papillary tumours, or any combination thereof, regardless of antecedent intra-vesicular treatment.
Procarbazine	procarbazine hydrochloride	Used to treat Hodgkin's Lymphoma (HL) as second line after relapse in chemotherapy and has also been used to treat other forms of lymphoma and solid tumours that have been resistant to other therapy. It is an anti-neoplastic agent - inhibits DNA replication as well as RNA and protein synthesis inside cancerous cells.



Product portfolio

Other Products		
BRAND	NON-PROPRIETARY NAME	USES
Actidose-Aqua *	activated charcoal	An activated charcoal suspension for the emergency treatment of acute poisoning and drug overdose for a number of substances.
Anbesol	Lidocaine hydrochloride chlorocresol cetylpyridinium chloride	A liquid or gel for the temporary relief of pain caused by recurrent mouth ulcers, denture irritation and teething.
Ashton and Parsons	Tincture of matricaria	A herbal product traditionally used in infants for the symptomatic relief of pain and gastric upset associated with teething.
Biorphen	orphenadrine hydrochloride	A liquid for Parkinson's disease (a degenerative process characterized by muscular rigidity and tremor), including Parkinson – like symptoms caused by other psychiatric drugs.
Broflex	trihexyphenidyl hydrochloride	A liquid for Parkinson's disease.
Buccastem & Buccastem M	prochlorperazine maleate	As a prescription treatment for nausea and vomiting, and for symptomatic treatment of other conditions such as vertigo. As an OTC product Buccastem M is used by migraine sufferers. It comes in a special buccal tablet formulation which adheres to the gum and releases the drug over one to two hours. This has a particular advantage as vomiting patients may encounter difficulties taking tablets orally.
Cafergot *	ergotamine tartrate and caffeine	For the management of acute attacks of migraine headache in patients who have not responded to alternative therapies.
Calcium Sandoz *	calcium glubionate and calcium lactobionate	A calcium supplement used to maintain calcium levels. It is given in neonatal hypocalcaemia. It may help to replace lost calcium and reduce the risk of broken bones in elderly patients with osteoporosis.
Deltacortril	prednisolone	Gastro-resistant tablets. Used for a wide range of disorders in which systemic corticosteroids are indicated, including allergies, arteritis, rheumatic fever, rheumatic disorders, autoimmune disorders etc.



Product portfolio

Other Products

Deseril *	methysergide	Used for the prevention of migraine in patients who have not responded to alternative therapies. It is also used in the management of diarrhoea associated with carcinoid disease.
Dicobalt Edetate *	dicobalt edetate	Dicobalt injection is a specific antidote for acute cyanide poisoning. In view of the difficulty of certain diagnosis in emergency situations, it is recommended that Dicobalt Edetate only be given when the patient is tending to lose or has lost consciousness.
Distamine	penicillamine	A disease modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (not osteoarthritis), Wilson's disease (toxic accumulation of copper), lead poisoning and cystinuria (formation of cystine stones in the kidneys).
Edrophonium *	edrophonium chloride	Myasthenia gravis, as a diagnostic test; to distinguish between overdosage and underdosage of cholinergic drugs in myasthenic patients; diagnosis of suspected 'dual block'; antagonist to non-depolarising neuromuscular blockage.
Forceval	multivitamin and mineral preparation	Capsules containing 24 essential vitamins and minerals (22 in the Junior capsules). Available on prescription unlike other preparations for use in patients with nutritional deficits due to disease e.g. AIDS, cancer, inflammatory bowel disease, or on restricted diets e.g. food intolerances, galactosaemia.
Hygroton *	chlortalidone	A diuretic to treat mild to moderate hypertension and oedema. Also used for diabetes insipidus (excessive urination).
Isocarboxazid *	isocarboxazid	For the treatment of the symptoms of depressive illness. (monoamine oxidase inhibitor).
Isoniazid *	Isoniazid	For all forms of pulmonary and extra-pulmonary tuberculosis.
Lysovir	amantadine	Used for the prevention and treatment of influenza A.
Menadiol *	menadiol diphosphate (as menadiol sodium diphosphate)	For the treatment of haemorrhage associated with a low blood level of prothrombin or factor vii. The main indication is obstructive jaundice (before and after surgery).



Product portfolio

Other Products

Metopirone *	metyrapone	Used in the diagnosis of certain problems of the adrenal glands. It is also used for the management of Cushing's syndrome (a rare disorder, mainly of females, characterized by a moonface, obesity and excessive growth of hair) and for oedema.
Neostigmine Bromide *	neostigmine bromide	Myasthenia gravis; paralytic ileus; post-operative urinary retention. Neostigmine Bromide Tablets are used mainly for the treatment of myasthenia gravis, a disease in which the muscles are weak and tire easily. They are also used when the normal movements of the intestine are absent and for the treatment of urinary retention after surgery.
Nu-Seals	aspirin, gastro-resistant	Low and standard dose aspirin with a protective coat to protect against GI side effects of aspirin. Low dose is used to prevent heart attacks and ischaemic strokes in patients with risk factors. Standard dose used for all aspirin indications except acute pain relief.
Oxymetholone *	oxymetholone	Oral tablet formulation synthetic male hormone, which enhances and repairs the body tissue-building process as a treatment for aplastic and refractory anaemias.
Pavacol D	pholcodine	A sugar free liquid for the symptomatic treatment of dry troublesome coughs.
Pentagastrin *	pentagastrin	Injectable synthetic polypeptide that stimulates the secretion of gastric acid, pepsin, and intrinsic factor. Diagnostic test for gastric acid secretion.
Periostat	doxycycline	Subantimicrobial dose doxycycline used for the treatment of periodontitis. By suppressing tissue destructive MMP enzymes, it has an anti-inflammatory rather than an antimicrobial action. Licensed in Europe through MRP.
Rogitine *	phentolamine	Used in the diagnosis of pheochromocytoma, a tumour of the adrenal gland and in the management of hypertensive episodes associated with pheochromocytoma.
Sinthrome *	acenocoumarol	An oral anticoagulant used in the treatment or prevention of thromboembolic disorders.
Slow-K *	potassium chloride	A potassium supplement used to correct low potassium levels associated with disease, poor diet or other drug therapy.
Symmetrel *	amantadine	Used in the treatment of Parkinson's disease and herpes zoster but only in those patients who you could expect to get a severe and painful rash. The syrup is also useful in the treatment and prevention of influenza type A.



Product portfolio

Other Products

Synacthen *	tetracosactide	Used in the diagnosis of adrenocortical insufficiency. Stimulates the formation of adrenal steroids (cortisol).
Synacthen Depot *	tetracosactide – slow release	A long acting formulation of Synacthen. In addition, it is used to treat various inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and osteoarthritis in short term use only.
Syntocinon *	oxytocin	A synthetic form of the hormone oxytocin, used in the induction of labour, the management of missed and incomplete abortion and to stop excessive bleeding following delivery.
Syntometrine *	ergometrine maleate and oxytocin	A combination of oxytocin and ergometrine used during the last stage of childbirth or following delivery of the placenta to prevent excessive bleeding.
Testosterone Enantate *	testosterone enantate	Used for the treatment of andropause - males who have too little or no endogenous testosterone production. Can also be used to treat breast cancer in females.
Uniflu with Gregovite C *	caffeine, codeine, diphenhydramine, paracetamol, phenylephrine, vitamin C	Uniflu tablets and Gregovite C tablets. For the relief from the signs and symptoms of colds and flu.
Vitamin E Suspension *	vitamin E suspension	Vitamin E deficiency in malabsorption disorders. It is the only UK licensed liquid formulation treatment for the correction of Vitamin E malabsorption in conditions such as including Cystic Fibrosis (CF, primary indication) and chronic cholestasis. The active ingredient is tocopherol acetate, a synthetic form of vitamin E.
Xenazine *	tetrabenazine	Xenazine IR is used for alleviation of a wide range of hyperkinetic movement disorders such as chorea associated with Huntington's disease (HD); tardive dyskinesias and tics associated with Tourettes syndrome. Tetrabenazine interferes with the normal action of dopamine to dampen neuro-transmission along motor pathways.

List contains licensed products

* Brand names appearing throughout this report are trademarks either owned by and/or licensed to Alliance Pharmaceuticals Limited, with the exception of Actidose-Aqua, trademark of Paddock Labs Inc, Cafergot, Calcium Sandoz, Deseril, Hygroton, Metopirone, Rogitine, Slow-K, Synacthen, Synacthen Depot, Syntocinon, Syntometrine, trademarks of Novartis AG, Symmetrel, trademark of Endo Pharmacetucials Inc and Gregovite C, trademark of G R Lane, Gelclair trademark of Helsinn, ImmuCyst trademark of Sanofi Pasteur, Xenazine trademark of Biovail.

